ENAM

Across TCGA pan-cancer cohorts, ENAM mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ENAM data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ENAM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENAM expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where ENAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.496	0.938	.017	9	view →
CCRCC	OS	Quartile	All	0.972	0.428	.045	4	view →
PDAC	DFS	Median	All	0.317	0.972	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ENAM–LUAD (DFS)

Open the LUAD breakdown →